FY2027 EPS Estimates for Transcat Reduced by HC Wainwright

Key Points

• HC Wainwright has revised its FY2027 earnings estimate for Transcat, Inc. to $2.45 per share, down from $2.58, while maintaining a "Buy" rating with a target price of $116.00.
• The consensus estimate for Transcat's current full-year earnings stands at $2.30, with a current market price of $90.43.
• Institutional investors hold a significant majority of Transcat's stock, owning 98.34% of the company, with several acquiring new positions recently.

Transcat, Inc. (NASDAQ:TRNS - Free Report) - HC Wainwright decreased their FY2027 earnings per share (EPS) estimates for Transcat in a report released on Friday, August 22nd. HC Wainwright analyst S. Buck now forecasts that the scientific and technical instruments company will earn $2.45 per share for the year, down from their previous forecast of $2.58. HC Wainwright currently has a "Buy" rating and a $116.00 target price on the stock. The consensus estimate for Transcat's current full-year earnings is $2.30 per share.

Several other equities research analysts have also recently commented on the company. Lake Street Capital initiated coverage on Transcat in a research note on Thursday, July 10th. They set a "buy" rating and a $105.00 price target for the company. Wall Street Zen raised Transcat from a "sell" rating to a "hold" rating in a report on Wednesday, May 28th. Three analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $112.20.

Transcat Stock Performance

Shares of Transcat stock traded down $0.54 during trading hours on Monday, hitting $83.95. 100,075 shares of the company were exchanged, compared to its average volume of 106,722. Transcat has a 1 year low of $67.56 and a 1 year high of $133.72. The company has a current ratio of 2.92, a quick ratio of 2.36 and a debt-to-equity ratio of 0.11. The business has a 50-day moving average of $83.24 and a 200-day moving average of $80.89. The stock has a market capitalization of $782.41 million, a price-to-earnings ratio of 58.71 and a beta of 0.71.

Transcat (NASDAQ:TRNS - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The scientific and technical instruments company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.40 by $0.19. Transcat had a return on equity of 6.66% and a net margin of 4.64%.The business had revenue of $76.42 million during the quarter, compared to analysts' expectations of $72.28 million.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Conestoga Capital Advisors LLC grew its holdings in Transcat by 13.7% during the second quarter. Conestoga Capital Advisors LLC now owns 1,088,471 shares of the scientific and technical instruments company's stock worth $93,565,000 after acquiring an additional 131,217 shares during the period. Neuberger Berman Group LLC grew its holdings in Transcat by 5.5% in the first quarter. Neuberger Berman Group LLC now owns 921,898 shares of the scientific and technical instruments company's stock valued at $68,635,000 after purchasing an additional 47,913 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in Transcat by 17.1% in the first quarter. T. Rowe Price Investment Management Inc. now owns 607,360 shares of the scientific and technical instruments company's stock valued at $45,218,000 after purchasing an additional 88,763 shares during the last quarter. Champlain Investment Partners LLC grew its holdings in Transcat by 7.6% in the first quarter. Champlain Investment Partners LLC now owns 598,026 shares of the scientific and technical instruments company's stock valued at $44,523,000 after purchasing an additional 42,376 shares during the last quarter. Finally, Royce & Associates LP grew its holdings in Transcat by 1.1% in the first quarter. Royce & Associates LP now owns 478,581 shares of the scientific and technical instruments company's stock valued at $35,630,000 after purchasing an additional 5,327 shares during the last quarter. Institutional investors and hedge funds own 98.34% of the company's stock.

Transcat Company Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.